Biotech Pioneer Biodimension Raises ₹8 Crore to Scale Biofabricated Human Tissue Alternatives Internationally
What is the news?
Bengaluru-based deep-tech and life sciences startup Biodimension has announced a successful funding round of ₹8 crore, spearheaded by the IAN Angel Fund. The investment round also witnessed strong backing from existing investor Campus Angels Network, alongside prominent individual backers Dr. Sampath Srisailam and angel investor Aaryan Baid. The capital infusion will primarily support the commercialization of its advanced products, bolster laboratory infrastructure, and strengthen its scientific teams as it expands into international corridors.
Why is it interesting?
Founded by the visionary trio of Manojkumar S., Ranjith Kumar Velusamy, and Pradeep Arunachalam, Biodimension is radically transforming the drug discovery and cosmetic testing landscapes. The company develops cutting-edge biofabricated human tissue and advanced organoid models designed to completely replace animal testing. Their proprietary portfolio which includes specialized platforms like BioDEpi, BioDFT, BioDPigma, and a unique Pan-Cancer Tumour Microenvironment (TME) Biobank provides highly accurate, human-relevant data for biotechnology and pharmaceutical giants.
This milestone further solidifies India’s position as a premium knowledge and innovation hub building scalable deep-tech solutions for the world. Biodimension has already institutionalized critical research and commercial collaborations across India and Singapore. Looking ahead, the founders plan to heavily scale their Bioassay-as-a-Service (BaaS) model and target immediate commercial expansion into Southeast Asian healthcare and pharmaceutical markets.
Read more: Biodimension secures Rs 8 Cr from IAN Angel Fund, others